Companies aim to simplify access to informative patient care data.
Guardant Health, a precision oncology company, and Flatiron Health, a health tech company, announced an initiative to integrate Guardant’s genomic profiling tests within Flatiron’s OncoEMR, a cloud-based electronic medical record (EMR) tool. Reportedly, the integration simplifies access to critical data that informs patient care decisions for over 2,000 clinicians within the Flatiron network, which includes more than 800 community-based cancer care locations across the US.
“Genomic profiling provides critical data that helps oncologists make timely and informed decisions about personalized treatment plans for their patients,” said Chris Freeman, chief commercial officer, Guardant Health. “This integration with the OncoEMR platform, which reaches almost 40 percent of U.S. community oncologists, will simplify access to our tests and enable a significant step forward in our mission to conquer cancer with data.”
Reference: Guardant Health, Flatiron Health Announce Integration of Guardant Genomic Profiling Tests Into OncoEMR® Platform. BusinessWire. October 31, 2023. Accessed October 31, 2023. https://www.businesswire.com/news/home/20231031158337/en/Guardant-Health-Flatiron-Health-Announce-Integration-of-Guardant-Genomic-Profiling-Tests-Into-OncoEMR%C2%AE-Platform
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Expands Farapulse PFA Approval to Persistent AF After Strong ADVANTAGE AF Trial Results
July 7th 2025Boston Scientific’s Farapulse Pulsed Field Ablation System is now approved for treating persistent atrial fibrillation, following 12-month data from the ADVANTAGE AF trial showing strong safety, high freedom from AF, and no major complications.